ClinicalTrials.gg
RecruitingNCT07287345Updated Jun 25, 2026

Colchicine's Effect on Inflammatory Markers

A Phase 4 interventional study of Colchicine (Colcrys®) and Placebo in Colchicine, Inflammation in Cardiac Surgery and Post Operative Atrial Fibrillation, sponsored by Ayesha Ather. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Ayesha Ather · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.

Planned enrollment
20th of 22
24 · median 236
Started
2026
the only one that year
Phase 4
4 of 22
1 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
Ayesha Ather

Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 20th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 4, and was the 21st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing colchicine in Atrial Fibrillation, or all of them as a file.
02

Study summary

This study wants to see if the medicine colchicine can help lower inflammation and reduce the chance of developing an irregular heartbeat (atrial fibrillation) after heart bypass surgery. Adults having coronary artery bypass surgery (CABG) can join. Participants will be randomly placed into one of two groups: one group will receive colchicine along with usual care, and the other will receive a placebo (a look-alike capsule with no medicine) along with usual care. Everyone will take a study capsule, and neither the patients nor the study team will know which capsule is being given. Everyone in the study will take study capsule, and neither the patients nor the study team will know who is receiving colchicine or placebo. Blood samples and health information will be collected before surgery; at 24, 48, 72, and 96 hours after surgery; and again at 10 days after surgery or at hospital discharge, whichever comes first. The investigators will look at inflammation marker levels, whether atrial fibrillation happens, and any side effects. This small study will help to generate effect size estimates and safety data that will help plan a larger study in the future.

03

Conditions studied

  • Colchicine
  • Inflammation in Cardiac Surgery
  • Post Operative Atrial Fibrillation
  • Inflammatory Markers
  • Colchicine Adverse Reaction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and older
  • Coronary artery bypass graft (CABG) planned procedure

Exclusion criteria

Exclusion Criteria:

  • History of atrial fibrillation
  • Off-pump CABG procedure
  • Current treatment with colchicine for any cause
  • to colchicine (as indicated by rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever)
  • Emergency cardiac surgery
  • Extracorporeal Membrane Oxygenation (ECMO) pre- or post-cardiac surgery
  • Heart transplant patients
  • Left ventricular assist device (LVAD) patients
  • Serum creatinine >2.0 mg/dL
  • Preoperative elevated CK or known myopathy
  • Severe liver disease or elevation of serum transaminases (>1.5 times the upper limit of 40 units/liter)
  • Chronic intestinal disease or blood dyscrasia
  • Unable to speak English
  • Pregnancy or lactation in women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Placebo comparator
    Standard of care and placebo

    placebo capsule

    Drug: Placebo

  • Experimental
    Standard of care and colchicine

    colchicine capsule

    Drug: Colchicine (Colcrys®)

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine dosing is based on actual body weight and renal function (creatinine clearance). Subjects will initiate study medication (placebo or active drug) 5 days prior to surgery and continue therapy for 10 days postoperatively or until hospital discharge, whichever occurs first. For patients weighing ≥70 kg: If CrCl \>30 mL/min: Colchicine 0.6 mg twice daily If CrCl \<30 mL/min: Colchicine 0.3 mg once daily For patients weighing \<70 kg: If CrCl \>30 mL/min: Colchicine 0.6 mg once daily If CrCl \<30 mL/min: Colchicine 0.3 mg every other day

  • DrugPlacebo

    Placebo dosing is based on actual body weight and renal function (creatinine clearance). Subjects will initiate study medication (placebo or active drug) 5 days prior to surgery and continue therapy for 10 days postoperatively or until hospital discharge, whichever occurs first. For patients weighing ≥70 kg: If CrCl \>30 mL/min: Placebo 0.6 mg twice daily If CrCl \<30 mL/min: Placebo 0.3 mg once daily For patients weighing \<70 kg: If CrCl \>30 mL/min: Placebo 0.6 mg once daily If CrCl \<30 mL/min: Placebo 0.3 mg every other day

06

What researchers measure

Primary outcomes

  1. Change in Inflammatory markers

    markers of inflammation (IL-6, CRP, IL-18, IL-1β, IL-8, and TNF-α) will be measured at predefined time points. Blood samples will be obtained as part of routine clinical care and analyzed using commercially available ELISA assays.

    Time frame: Baseline (pre-surgery), 24, 48, 72, 96 hours post-surgery and 10 days postoperatively or at discharge, whichever occurs first.

  2. Rate of post-operative atrial fibrillation (POAF)

    Postoperative atrial fibrillation (POAF) incidence will be assessed through daily chart review.

    Time frame: Through discharge (up to 15 days)

Secondary outcomes

  1. Number of participants discontinuing treatment

    treatment discontinuation rates due to adverse events will be measured

    Time frame: Through discharge (up to 15 days)

  2. Change in Liver Function

    Assessed as the impact on clinical biomarkers, i.e., ALT, AST in units per liter.

    Time frame: Baseline and Post operatively (approximately 24 hours)

  3. Change in creatinine level

    Assessed as the impact on clinical biomarkers, i.e., creatinine level in mg/dl

    Time frame: Baseline through discharge (up to 15 days)

  4. Creatine kinase level

    Assessed as the impact on clinical biomarkers, creatine kinase (i.e., CK level) in units per liter

    Time frame: Through discharge (up to 15 days)

  5. Complete blood count (CBC).

    Assessed as the impact on clinical biomarker complete blood count (CBC).

    Time frame: Through discharge (up to 15 days)

07

Study locations

1 of 1 sites recruiting
  • University of Kentucy
    Lexington, Kentucky 40536, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 11 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 17, 2025
StartActual
Jan 16, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07287345
Lead sponsor
Ayesha Ather
Responsible party
Ayesha Ather (Principal Investigator, University of Kentucky) — Sponsor-investigator
First posted
Dec 17, 2025
Start date
Jan 16, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jun 25, 2026

Study contacts

Ayesha Ather
Contact
ayesha.ather@uky.edu
8592184157
Sibu Saha, MD
study director · University of Kentucky

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion